News
Gyrus Capital has held a final close on a €700 million single-asset continuation vehicle for Essential Pharma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback